Array BioPharma (ARRY) Posts Mixed Q3 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $3.19 -3.33%
Revenue Growth %: -18.0%
Financial Fact:
Loss from operations: -24M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Revenue Growth %: -18.0%
Financial Fact:
Loss from operations: -24M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Array BioPharma, Inc. (Nasdaq: ARRY) reported Q3 loss of $0.20, $0.05 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $17.8 million versus the consensus estimate of $19.58 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Array Technologies (ARRY) PT Lowered to $6 at BMO Capital
- Array Technologies (ARRY) PT Lowered to $7 at JPMorgan
- Rithm Capital Corp. (RITM) Tops Q3 EPS by 6c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
